# High-Risk Nonsecretory Multiple Myeloma With Poor Response to Daratumumab-Based Chemotherapy

## TL;DR

This case report describes a patient with nonsecretory multiple myeloma who did not respond well to daratumumab-based chemotherapy.

## Contribution

The paper highlights the poor response to daratumumab in a nonsecretory multiple myeloma case, suggesting treatment challenges in this rare variant.

## Key findings

- The patient had nonsecretory multiple myeloma confirmed by bone marrow studies.
- The patient showed no response to daratumumab-based chemotherapy.
- This case underscores the need for tailored treatment approaches for nonsecretory multiple myeloma.

## Abstract

Nonsecretory multiple myeloma (NSMM) is the variant of multiple myeloma defined by no detectable M protein secretion in serum or urine electrophoresis. Due to the lack of detectable M spike, diagnosis is often challenging and relies on bone marrow studies. As studies specifically focusing on NSMM are lacking, the current treatment guidelines are based on studies in secretory multiple myeloma. In this case report, we describe a 77-year-old female patient with a typical presentation of NSMM who did not respond to a chemotherapy regimen based on daratumumab.